Drug profile · INN
sildenafil citrate
SILDENAFIL CITRATE
sildenafil citrate (SILDENAFIL CITRATE) is a phosphodiesterase 5a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — sildenafil citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
sildenafil citrate (SILDENAFIL CITRATE) is a phosphodiesterase 5a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 5A inhibitor
Primary target: cGMP-specific 3',5'-cyclic phosphodiesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sildenafil citrate?
sildenafil citrate (SILDENAFIL CITRATE) is a phosphodiesterase 5a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sildenafil citrate?
SILDENAFIL CITRATE is a marketed brand name for sildenafil citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sildenafil citrate?
sildenafil citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.